MCM
KERX

Mazama Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Mazama Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,934
Closed -$27K – 309
2014
Q4 		$27K Hold
1,934
– – 0.01% 252
2014
Q3 		$27K Buy
+1,934
New +$29.6K 0.01% 243
2013
Q4 		– Sell
-5,310
Closed -$54K – 291
2013
Q3 		$54K Buy
5,310
+1,692
+47% +$15.1K 0.03% 154
2013
Q2 		$27K Buy
+3,618
New +$28.3K 0.02% 169

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Mazama Capital Management's KERX Position: Q1 2015 in Review

Mazama Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 1,934 shares — an estimated $27K sold.

Mazama Capital Management first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $54K in Q3 2013. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • Mazama Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • Mazama Capital Management sold 1,934 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $27K.
  • Mazama Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Mazama Capital Management's Keryx Biopharmaceuticals Inc position peaked at $54K in Q3 2013.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on Mazama Capital Management's 13F filing for Q1 2015, filed 15 May 2015.